The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: FTSE 100 Slides; Lloyds Tumbles After Results

Thu, 30th Jul 2020 08:46

(Alliance News) - A dovish tone from the US Federal Reserve was unable to lift the FTSE 100 index in early dealings in London on Thursday amid a deluge of earnings reports, with Lloyds Banking the worst blue-chip performer after swinging to an interim loss.

Focus now turns to second-quarter GDP readings due from Germany and the US later in the day.

The FTSE 100 index was down 50.23 points, or 0.8%, at 6,081.23 early Thursday. The mid-cap FTSE 250 index was down 92.49 points, or 0.5%, at 17,155.17 and the AIM All-Share index was down 0.4% at 892.40.

The Cboe UK 100 index was down 0.9% at 606.05. The Cboe 250 was down 0.5% at 14,567.35 and the Cboe Small Companies flat at 9,134.15.

In mainland Europe, the CAC 40 in Paris was down 0.5% while the DAX 30 in Frankfurt was down 1.1% early Thursday.

Stocks ended higher in the US in the wake of the Fed's cautious tone, but trade in Asia overnight was more downbeat.

In Asia on Thursday, the Japanese Nikkei 225 index closed down 0.3%. In China, the Shanghai Composite ended down 0.2% while the Hang Seng index in Hong Kong is down 0.7%.

Fed Chair Jerome Powell warned that the spiking number of new coronavirus cases in recent weeks was likely already starting to hinder the fragile economic recovery from the pandemic-induced recession.

"The path forward for the economy is extraordinarily uncertain," Powell told a press conference. US second-quarter GDP data, out on Thursday, would likely be the worst numbers posted in modern history, he noted.

Powell said there is "clearly a risk" that the virus resurgence is hurting economic growth and the labour market rebound, pointing to early data showing that the initially steady recovery in household spending was hitting headwinds.

At its latest meeting, the Fed kept its benchmark interest rate on hold at near-zero levels.

The bank said in its statement that it would increase its holdings of Treasury bills and mortgage-backed securities "at least at the current pace to sustain smooth market functioning".

The dollar dropped Wednesday evening after the Fed's update, but has since gained back some ground.

Sterling was quoted at USD1.2959 early Thursday, lower than USD1.2968 at the London equities close on Wednesday. Sterling had surged just above the USD1.30 mark after the Fed decision.

The euro traded at USD1.1754 early Thursday, down on USD1.1767 late Wednesday. Against the yen, the dollar was quoted at JPY105.07, flat versus JPY105.08.

Gold was quoted at USD1,949.89 an ounce early Thursday, lower than USD1,955.22 on Wednesday. Brent oil was trading at USD43.36 a barrel early Thursday, soft on USD43.42 late Wednesday.

At the bottom of the FTSE 100 was Lloyds Banking Group, tumbling 7.1%. The lender reported a pretax loss of GBP602 million for the half-year to June 30, swinging from a profit of GBP2.90 billion a year ago.

Net income was down 16% to GBP7.41 billion, with net interest income down 11%.

The bank took a GBP3.82 billion impairment in the half - including GBP2.4 billion in the second quarter - up from GBP579 a year ago, and said it expects its impairments for the full-year to be between GBP4.5 billion to GBP5.5 billion.

The impairments taken in the half reflected "a significant deterioration in forward looking economic outlook".

Looking to the remainder of the year, Lloyds said: "There have been early signs of recovery in the group's core markets, mainly in consumer spending and the housing market, but the outlook remains highly uncertain and the impact of lower rates and economic fragility will continue for at least the rest of the year."

Compass shares shed 2.0% after the contract caterer reporting a 44% slump in organic revenue for the third quarter, bringing its year-to-date slide to 14%.

The third-quarter decline was led by Europe, down 54%. North America was down 45% and Rest of World down 20%.

Compass's operating margin for the quarter was minus 6.3%.

"The pace at which our volumes will recover is still unclear, especially given a possible increase in local lockdowns. We are encouraged by the relative improvement in performance in June, as well as the early signs of an acceleration in first time outsourcing opportunities. In the meantime, we continue to work with our clients to help them reopen safely. We are proactively managing the business, reducing our costs, rebuilding our margins and investing to strengthen our competitive advantages," said Compass.

Shares in Royal Dutch Shell were little moved, with 'A' shares down 0.3% and 'B' shares down 0.4%, despite the oil major reporting a sizeable second quarter impairment.

Adjusted earnings - previously referred to as CCS earnings attributable to shareholders excluding identified items - slumped to just USD638 million in the second quarter from USD3.46 billion a year ago.

Including a USD16.8 billion impairment charge - taken "as a result of revised medium- and long-term price and refining margin outlook assumptions in response to the Covid-19 pandemic and macroeconomic conditions as well as energy market demand and supply fundamentals" - Shell posted a loss attributable to shareholders of USD18.13 billion versus income of USD3.00 billion a year ago.

AstraZeneca shares rose 2.3%. The pharmaceutical firm reported a 12% rise in total revenue in the first half of the year to USD12.63 billion, while core earnings per share rose 24% to USD2.01.

The FTSE 100 constituent said its 2020 full-year guidance was unchanged at high single-digit to low double-digit percentage growth in revenue and mid- to high-teens growth in core EPS.

Astra held its first interim dividend steady at USD0.90 per share.

The economic events calendar on Thursday has Germany GDP readings at 0900 BST, eurozone unemployment at 1000 BST and US GDP and jobless claims figures at 1330 BST.

The US GDP figure due later will be "ugly", said Lloyds Banking.

"While the forecast fall is very large, activity rebounded in late May and through June. The focus now is on whether growth is faltering in July. For that reason, today's weekly jobless claims will also draw considerable attention," said Lloyds.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.